-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $21

Benzinga·02/04/2025 11:52:33
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $8 to $21.